

SmartPA Criteria Proposal

Drug/Drug Class:	Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit
First Implementation Date:	January 22, 2004
Proposed Date:	June 18, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Janus kinase (JAK) is a cytoplasmic protein tyrosine kinase that is essential for signal transduction to the nucleus from common plasma membrane receptors for some interleukins. JAKs activate signal transducers and activators of transcriptions which regulate gene function and intracellular activity. Inhibiting the JAK enzymes will prevent cytokine or growth factor-mediated gene expression and intracellular activity thus decreasing immunological responses. All JAK inhibitors are available in an oral formulation and are classified as targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs). tsDMARDs may be an appropriate therapy choice in participants who do not prefer agents that have a subcutaneous or intravenous administration technique. These agents are most commonly used in participants with moderate to severe rheumatoid arthritis after DMARDs and a failure of at least two biologic agents. There are many JAK inhibitors marketed including Olumiant® (baricitinib), Rinvoq™ (upadactinib), Xeljanz® and Xeljanz® XR (tofacitinib). Tofacitinib can be used in combination with methotrexate or as monotherapy in participants with an inadequate response to methotrexate alone. Baricitinib is limited to use only in participants who have not responded to TNF inhibitor therapy. Upadactinib can be used as monotherapy or in combination with methotrexate or other non-biological DMARDs. Initiation of therapy should be avoided in those with an ANC < 1000 mm³, lymphocyte count < 500 μL, and/or a hemoglobin count of < 9 g/dL. The FDA does not recommend using JAK inhibitors with azathioprine or cyclosporine. Some common adverse effects include infections, nausea, and nasopharyngitis. A boxed warning for all JAK inhibitors is an increased risk of serious infection (tuberculosis) and malignancies (lymphoma). Baricitinib has an additional boxed warning for an increased risk of thrombosis.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> • Xeljanz® 	<ul style="list-style-type: none"> • Olumiant® • Rinvoq™ • Xeljanz® XR

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors
- Age range: All appropriate MO HealthNet participants aged 18 years or older

Approval Criteria

- **Participants aged 18 years or older AND**
- **Adequate therapeutic 6 month trial of tumor necrosis factor (TNF) inhibitors defined as:**
 - **Combination therapy of 2 TNF inhibitors OR**
 - **Monotherapy of 1 TNF inhibitor AND**
- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented trial period of preferred agents (**6 months of therapy**)
 - Documented ADE/ADR to preferred agents **AND**
- **For Xeljanz XR: clinical consultant review for medical necessity AND**
- Documented diagnosis of rheumatoid arthritis:
 - Adequate therapeutic trial of methotrexate in the past 720 days **OR**
 - Contraindication to methotrexate therapy **OR**
- Documentation of appropriate diagnosis for requested agent:

Generic	Brand	Indication
Baricitinib	Olumiant®	<ul style="list-style-type: none"> • Rheumatoid arthritis
Tofacitinib	Xeljanz® Xeljanz® XR	<ul style="list-style-type: none"> • Psoriatic arthritis • Rheumatoid arthritis • Ulcerative colitis
Upadacitinib	Rinvoq™	<ul style="list-style-type: none"> • Rheumatoid arthritis

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
 Rule Type: PDL

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Default Approval Period

1 year

References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
2. USPDI, Micromedex; 2020.
3. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.
4. Olumiant [package insert]. Indianapolis, IN: Lilly USA LLC; 2019.
5. Rinvoq [package insert]. North Chicago, IL: AbbVie Inc; 2019.
6. Xeljanz/Xeljanz XR [package insert]. New York, NY: Pfizer; 2019.
7. Cohen, S. & Cannella, A. (2020). Treatment of rheumatoid arthritis in adults resistant to initial conventional nonbiologic DMARD therapy. In P.L. Romain (Ed.), *UpToDate*.
8. Evidence-Based Medicine and Fiscal Analysis: “Targeted Immune Modulators: Janus Kinase (JAK) Inhibitors – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; April 2020.
9. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Singh et al. *Arthritis Care & Research* – DOI 10.1002/acr.22783
10. Evidence-Based Medicine Analysis: “Targeted Immune Modulators (Biologics – DMARDS)”. UMKC-DIC; April 2020.

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.